Yesterday | BNET
Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
Is this a rare case of Teva Pharmaceutical being forced to swallow its own bitter medicine? The world's largest generic manufacturer, founded on its unflinching willingness to challenge the patented protection of branded products owned by other drugmakers, is suing generic rival Mylan .
Friday | Canada.com
Orthotist Matt McLean fits Vicki Dutton with a WalkAide in Victoria, B.C. August 26, 2009.
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
People with multiple sclerosis who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology , the medical journal of the American Academy of Neurology.
Facet Biotech Reports Third Quarter 2009 Financial Results
"We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech.
Boy hopes for summit on vitamin D
A science summit exploring possible links between multiple sclerosis and a lack of vitamin D may be held in Scotland next year, it has emerged.
Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR
Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.
Multiple sclerosis susceptibility alleles in African Americans
E-mail: Jorge.Oksenberg@ucsf.edu Received 2 July 2009; Revised 11 September 2009; Accepted 15 September 2009; Published online 29 October 2009.
New Tool To Accelerate Discovery Of Autoimmune Disease Mechanisms And Therapies
Multiple Sclerosis IT / Internet / E-mail Article Date: 31 Oct 2009 Currently, 5 - 8% of the U.S. population is afflicted with an autoimmune disease.
Bay Bridge closure puts naked clowns on my radar
Have you ever noticed that when routines are interrupted, people are more likely to strike up conversations with strangers? My morning took an unexpected turn yesterday when I arrived at the Macarthur BART station to find a news van and television crew out front, filming the hordes of commuters who were in line to purchase train tickets.
Genetic variants of CC chemokine genes in experimental autoimmune...
E-mail: johan.ockinger@ki.se 13 These authors contributed equally to this study.
How Multiple Sclerosis Sufferers Can Cope with Fatigue
Fatigue is one of the most common problems that Multiple Sclerosis sufferers will contend with.
Administrators called in as biotech makes a hash of things
A treatment using cannabis extract to treat cancer, and a novel way to ease period pain, are up for sale after the biotechnology company developing the drugs went bust.
4-Star Stocks Poised to Pop: Elan
Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, Irish biotech Elan has earned a respected four-star ranking .
Novartis says MS therapy drug reduces relapses
Swiss drug maker Novartis AG recently noted its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Study May Uncover New Cause of Multiple Sclerosis
The cause of multiple sclerosis, a chronic, often debilitating disease that attacks the central nervous system, has puzzled doctors for decades.
How does Ore. candidate roll? With MS, on a Segway
SALEM, Ore. - Bill Bradbury isn't just running for Oregon governor. He's zipping _ on a Segway.
Light Touch Helps Grip of MS Patients
Using a gentle touch may help make it easier for people with multiple sclerosis to pick up and hold objects, a new study suggests.
Biotech Stocks: Biogen, Elan fall on Tysabri drug woes
Partners Biogen Idec and Elan Corp. led drug stocks lower Friday as European pharmaceutical regulators said they are reviewing the safety of Tysabri, the companies' drug for treating multiple sclerosis.
'Medical marijuana' -- or legalization?
My post about a oemedical marijuanaa stirred a lot of comments, some of them approving, the vast majority hostile and vituperative -- and one or two actually threatening.
NewSOUTHSIDE NOTES: Sweetwater Writer's Group has lively meeting
Susan D. Brandenburg/Special - 10/15/09 - Sweetwater Writer's Group planning Meeting in Library at Sweetwater Club Oct.
Also on Topix